Related Experiment Videos
Acute nicotinic blockade produces cognitive impairment in normal humans
P A Newhouse1, A Potter, J Corwin
1Department of Psychiatry, University of Vermont College of Medicine, Burlington 05401.
Psychopharmacology
|January 1, 1992
Summary
Mecamylamine, a nicotinic antagonist, impaired cognitive functions like learning and recognition memory in healthy males. Even low doses affected performance, suggesting nicotinic receptor blockade impacts cognition.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Nicotinic acetylcholine receptors play crucial roles in cognitive processes.
- Understanding the impact of nicotinic receptor blockade on cognition is essential for various neurological and psychiatric conditions.
Purpose of the Study:
- To investigate the cognitive effects of acute blockade of nicotinic receptor function using mecamylamine in healthy young males.
- To determine dose-dependent effects of mecamylamine on learning, memory, and reaction time.
Main Methods:
- A placebo-controlled, double-blind study administering single oral doses of mecamylamine (5, 10, 20 mg) to healthy male participants.
- Cognitive assessment using the Repeated Acquisition task and a recognition memory task.
- Measurement of reaction time and physiological indicators of ganglionic blockade.
Main Results:
- A significant increase in learning errors and a slower acquisition curve were observed at the 20 mg dose of mecamylamine.
- Dose-related increases in false alarms were noted in the recognition memory task.
- Reaction times were dose-dependently slowed across several tasks, with minimal behavioral side effects.
Conclusions:
- Acute blockade of nicotinic receptor function by mecamylamine leads to measurable cognitive impairment in healthy individuals.
- These findings highlight the significance of nicotinic pathways in maintaining normal cognitive function, even in non-smokers.